Efficacy, tolerability, and safety of DFN-15 (celecoxib oral solution, 25 mg/ml) in the acute treatment of episodic migraine: A randomized, double-blind, placebo-controlled study
Headache: The Journal of Head and Face Pain Oct 31, 2019
Lipton RB, et al. - Researchers examined if relative to placebo, 120 mg DFN-15, an oral, ready-made liquid solution of celecoxib, is efficacious, tolerable, and safe for the acute treatment of migraine. In this randomized, double-blind, placebo-controlled, 567 adults treated a migraine with 120 mg DFN-15 or placebo as soon as possible after the onset of pain of moderate to severe intensity. Outcomes revealed significantly higher efficacy of DFN-15 vs placebo for the acute treatment of migraine, with a generally favorable tolerability and safety profile.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries